与他莫昔芬治疗相关的子宫内膜异位症中发生的良性、交界性和恶性子宫内膜样肿瘤形成。

Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy.

作者信息

McCluggage W G, Bryson C, Lamki H, Boyle D D

机构信息

Department of Pathology, Royal Group of Hospitals Trust, Belfast, Northern Ireland.

出版信息

Int J Gynecol Pathol. 2000 Jul;19(3):276-9. doi: 10.1097/00004347-200007000-00013.

DOI:10.1097/00004347-200007000-00013

PMID:10907178

Abstract

Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenocarcinoma, and as recently suggested, proliferative changes within endometriosis. This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis in a patient taking tamoxifen. There were also foci of benign and borderline endometrioid adenofibroma in the same ovary and a synchronous endometrioid endometrial adenocarcinoma in the uterus. The spectrum of benign, borderline, and malignant endometrioid neoplasia arising within endometriosis suggests that tamoxifen, as a result of its estrogenic effects, may cause proliferative and, in rare instances, malignant changes in endometriosis.

摘要

他莫昔芬治疗可能导致多种子宫内膜增生性病变，包括腺癌，并且正如最近所表明的，还可导致子宫内膜异位症内的增生性改变。本报告描述了1例服用他莫昔芬的患者，其卵巢子宫内膜异位症发生了子宫内膜样腺癌。同一卵巢中还存在良性及交界性子宫内膜样腺纤维瘤灶，且子宫中存在同步性子宫内膜样腺癌。子宫内膜异位症内出现的良性、交界性和恶性子宫内膜样肿瘤谱表明，他莫昔芬由于其雌激素效应，可能导致子宫内膜异位症发生增生性改变，在罕见情况下还可导致恶性改变。